Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking.
The BioICOPER Follow-up Study aims to analyze the influence of biomarker evolution on clinical symptomatology (particularly chronic fatigue) and vascular health after four years of follow-up among 400 participants previously included in the original BioICOPER cohort.
Advanced proteomic analysis, vascular function assessment, and machine-learning-based predictive modeling will be used to identify biomarkers associated with disease progression, stratified by sex. This project will contribute to personalized clinical management of long COVID and improved diagnostic and therapeutic strategies in primary care.
Adults ≥18 years old.
Confirmed previous SARS-CoV-2 infection.
Diagnosis of long COVID according to WHO criteria.
Participation in the baseline BioICOPER study.
Acute illness preventing participation.
Cognitive or physical impairment limiting data collection.
Withdrawal of informed consent.
Age < 18 years old
Instituto de Investigación Biomédica de Salamanca
Lead sponsor
Carlos III Health Institute
Collaborator